FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2019227458> ?p ?o ?g. }

• W2019227458 endingPage "991" @default.
• W2019227458 startingPage "983" @default.
• W2019227458 abstract "Previous studies from our laboratories have shown that (a) Triapine() is a potent inhibitor of ribonucleotide reductase activity and (b) hydroxyurea-resistant L1210 leukemia cells are fully sensitive to Triapine. In an analogous manner, Triapine was similarly active against the wild-type and a hydroxyurea-resistant subline of the human KB nasopharyngeal carcinoma. Triapine was active in vivo against the L1210 leukemia over a broad range of dosages and was curative for some mice. This agent also caused pronounced inhibition of the growth of the murine M109 lung carcinoma and human A2780 ovarian carcinoma xenografts in mice. Optimum anticancer activity required twice daily dosing due to the duration of inhibition of DNA synthesis which lasted about 10 hr in L1210 cells treated with Triapine in vivo. DNA synthesis in normal mouse tissues (i.e. duodenum and bone marrow) uniformly recovered faster than that in L1210 leukemia cells, demonstrating a pharmacological basis for the therapeutic index of this agent. Triapine was more potent than hydroxyurea in inhibiting DNA synthesis in L1210 cells in vivo, and the effects of Triapine were more pronounced. In addition, the duration of the inhibition of DNA synthesis in leukemia cells from mice treated with Triapine was considerably longer than in those from animals treated with hydroxyurea. Combination of Triapine with various classes of agents that damage DNA (e.g. etoposide, cisplatin, doxorubicin, and 1-acetyl-1,2-bis(methylsulfonyl)-2-(2-chloroethyl)hydrazine) resulted in synergistic inhibition of the L1210 leukemia, producing long-term survivors of tumor-bearing mice treated with several dosage levels of the combinations, whereas no enhancement of survival was found when Triapine was combined with gemcitabine or cytosine arabinoside. The findings demonstrate the superiority of Triapine over hydroxyurea as an anticancer agent and further suggest that prevention by Triapine of repair of DNA lesions created by agents that damage DNA may result in efficacious drug combinations for the treatment of cancer." @default.
• W2019227458 created "2016-06-24" @default.
• W2019227458 creator A5004046021 @default.
• W2019227458 creator A5006607723 @default.
• W2019227458 creator A5023479145 @default.
• W2019227458 creator A5043512123 @default.
• W2019227458 creator A5047051679 @default.
• W2019227458 creator A5062805438 @default.
• W2019227458 creator A5076719152 @default.
• W2019227458 creator A5082820102 @default.
• W2019227458 date "2000-04-01" @default.
• W2019227458 modified "2023-09-24" @default.
• W2019227458 title "Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity" @default.
• W2019227458 cites W1505281346 @default.
• W2019227458 cites W1508340483 @default.
• W2019227458 cites W1535189264 @default.
• W2019227458 cites W1577909961 @default.
• W2019227458 cites W1966431174 @default.
• W2019227458 cites W1971437863 @default.
• W2019227458 cites W1981752993 @default.
• W2019227458 cites W1984896504 @default.
• W2019227458 cites W1986778880 @default.
• W2019227458 cites W2006277511 @default.
• W2019227458 cites W2015295078 @default.
• W2019227458 cites W2068973845 @default.
• W2019227458 cites W2074770798 @default.
• W2019227458 cites W2078010998 @default.
• W2019227458 cites W2081059256 @default.
• W2019227458 cites W2088706737 @default.
• W2019227458 cites W2143594378 @default.
• W2019227458 cites W2178778111 @default.
• W2019227458 cites W2952760252 @default.
• W2019227458 cites W4293311245 @default.
• W2019227458 doi "https://doi.org/10.1016/s0006-2952(99)00419-0" @default.
• W2019227458 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10692563" @default.
• W2019227458 hasPublicationYear "2000" @default.
• W2019227458 type Work @default.
• W2019227458 sameAs 2019227458 @default.
• W2019227458 citedByCount "329" @default.
• W2019227458 countsByYear W20192274582012 @default.
• W2019227458 countsByYear W20192274582013 @default.
• W2019227458 countsByYear W20192274582014 @default.
• W2019227458 countsByYear W20192274582015 @default.
• W2019227458 countsByYear W20192274582016 @default.
• W2019227458 countsByYear W20192274582017 @default.
• W2019227458 countsByYear W20192274582018 @default.
• W2019227458 countsByYear W20192274582019 @default.
• W2019227458 countsByYear W20192274582020 @default.
• W2019227458 countsByYear W20192274582021 @default.
• W2019227458 countsByYear W20192274582022 @default.
• W2019227458 countsByYear W20192274582023 @default.
• W2019227458 crossrefType "journal-article" @default.
• W2019227458 hasAuthorship W2019227458A5004046021 @default.
• W2019227458 hasAuthorship W2019227458A5006607723 @default.
• W2019227458 hasAuthorship W2019227458A5023479145 @default.
• W2019227458 hasAuthorship W2019227458A5043512123 @default.
• W2019227458 hasAuthorship W2019227458A5047051679 @default.
• W2019227458 hasAuthorship W2019227458A5062805438 @default.
• W2019227458 hasAuthorship W2019227458A5076719152 @default.
• W2019227458 hasAuthorship W2019227458A5082820102 @default.
• W2019227458 hasConcept C104292427 @default.
• W2019227458 hasConcept C104317684 @default.
• W2019227458 hasConcept C150903083 @default.
• W2019227458 hasConcept C185592680 @default.
• W2019227458 hasConcept C207001950 @default.
• W2019227458 hasConcept C4710235 @default.
• W2019227458 hasConcept C552990157 @default.
• W2019227458 hasConcept C55493867 @default.
• W2019227458 hasConcept C64241487 @default.
• W2019227458 hasConcept C86803240 @default.
• W2019227458 hasConcept C98274493 @default.
• W2019227458 hasConceptScore W2019227458C104292427 @default.
• W2019227458 hasConceptScore W2019227458C104317684 @default.
• W2019227458 hasConceptScore W2019227458C150903083 @default.
• W2019227458 hasConceptScore W2019227458C185592680 @default.
• W2019227458 hasConceptScore W2019227458C207001950 @default.
• W2019227458 hasConceptScore W2019227458C4710235 @default.
• W2019227458 hasConceptScore W2019227458C552990157 @default.
• W2019227458 hasConceptScore W2019227458C55493867 @default.
• W2019227458 hasConceptScore W2019227458C64241487 @default.
• W2019227458 hasConceptScore W2019227458C86803240 @default.
• W2019227458 hasConceptScore W2019227458C98274493 @default.
• W2019227458 hasIssue "8" @default.
• W2019227458 hasLocation W20192274581 @default.
• W2019227458 hasLocation W20192274582 @default.
• W2019227458 hasOpenAccess W2019227458 @default.
• W2019227458 hasPrimaryLocation W20192274581 @default.
• W2019227458 hasRelatedWork W1500617698 @default.
• W2019227458 hasRelatedWork W1577945616 @default.
• W2019227458 hasRelatedWork W1580038011 @default.
• W2019227458 hasRelatedWork W1985154969 @default.
• W2019227458 hasRelatedWork W1988528612 @default.
• W2019227458 hasRelatedWork W2019655371 @default.
• W2019227458 hasRelatedWork W2026892971 @default.
• W2019227458 hasRelatedWork W2038350694 @default.
• W2019227458 hasRelatedWork W2060675617 @default.
• W2019227458 hasRelatedWork W2135592928 @default.
• W2019227458 hasVolume "59" @default.

• next